http://jpet.aspetjournals.org/content/jpet/371/1/1.full.pdf … This is big news; an antipsychotic that's NOT a D2 agonist.
-
-
https://academic.oup.com/schizophreniabulletin/article/45/Supplement_2/S199/5434347 … Other antipsychotics don't do anything for the negative symptoms of schizophrenia (the cognitive impairment and loss of motivation.) This one does: 0.48 effect size on negative symptoms in an RCT!
Show this thread -
What's cool is that it was discovered phenotypically; researchers put mice in "SmartCube" boxes where their behavior was monitored on video through a variety of tests. This allows drugs to be clustered (as anxiolytics, stimulants, etc) based on their effects on behavior.
Show this thread -
It's a high-tech version of what psychopharmacology used to be like in the 1950's -- give some chemicals to mice and see if they act funny. This allows the discovery of totally new mechanisms of action.
Show this thread -
I learned about this from Emer Leahy, the founder of Psychogenics, the biotech company that built the SmartCube and pioneered this behavioral-phenotype approach to CNS drug discovery. It sounded crazy 20 years ago, but now the results are coming in and they're astonishing.
Show this thread -
In vivo phenotypic screening: it's how you do exploratory science when computing power is abundant! And it works! (Hint: we're doing it at Daphnia Labs too.)
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.